Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

132.23B

Market cap132.23B

Price-Earnings ratio

277.52

Price-Earnings ratio277.52

Dividend yield

2.92%

Dividend yield2.92%

Average volume

8.45M

Average volume8.45M

High today

$107.56

High today$107.56

Low today

$99.00

Low today$99.00

Open price

$106.11

Open price$106.11

Volume

10.13M

Volume10.13M

52 Week high

$119.96

52 Week high$119.96

52 Week low

$62.07

52 Week low$62.07

GILD News

TipRanks 6h

Gilead Sciences Reports Strong Start to 2025

Gilead Sciences ( (GILD) ) has released its Q1 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors. Gilead Sciences, In...

Benzinga 13h

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance

Gilead Sciences, Inc. GILD released its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. The Details: Gilead...

Sherwood News 13h

Gilead slips after sales miss

Gilead Sciences slipped 3% in after-hours trading after it reported sales that missed Wall Street estimates, though earnings came in better than expected. The...

Analyst ratings

63%

of 30 ratings

Buy

63.3%

Hold

33.3%

Sell

3.3%

More GILD News

TipRanks 3d

Gilead assumed at Overweight from Neutral at Cantor Fitzgerald

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, up from $100, as t...

Benzinga 4d

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer

Gilead Sciences, Inc. GILD on Monday released topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy (sacituzumab govitecan-hziy) plus Merck &...

Simply Wall St 4d

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breas...

TipRanks 4d

Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint

Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significantly improved...

TipRanks 5d

Gilead Sciences: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

In a report released on April 17, Tim Anderson from Bank of America Securities reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price...